481 related articles for article (PubMed ID: 31586527)
21. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
22. Future directions in haploidentical hematopoietic stem cell transplantation.
Vittayawacharin P; Kongtim P; Ciurea SO
Hematology; 2024 Dec; 29(1):2366718. PubMed ID: 38889342
[TBL] [Abstract][Full Text] [Related]
23. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis.
Ruggeri A; Rocha V; Masson E; Labopin M; Cunha R; Absi L; Boudifa A; Coeffic B; Devys A; De Matteis M; Dubois V; Hanau D; Hau F; Jollet I; Masson D; Pedron B; Perrier P; Picard C; Ramouneau-Pigot A; Volt F; Charron D; Gluckman E; Loiseau P
Haematologica; 2013 Jul; 98(7):1154-60. PubMed ID: 23242594
[TBL] [Abstract][Full Text] [Related]
24. [Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (Part 1)].
Blaise D; Nguyen S; Bay JO; Chevallier P; Contentin N; Dhédin N; Duléry R; Eliaou JF; Rubio MT; Suarez F; Bulabois CE; Cornillon J; Huynh A; Magro L; Michallet M; Paillard C; Turlure P; Yakoub-Agha I;
Pathol Biol (Paris); 2014 Aug; 62(4):180-4. PubMed ID: 24973859
[TBL] [Abstract][Full Text] [Related]
25. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.
Brunstein CG; Fuchs EJ; Carter SL; Karanes C; Costa LJ; Wu J; Devine SM; Wingard JR; Aljitawi OS; Cutler CS; Jagasia MH; Ballen KK; Eapen M; O'Donnell PV;
Blood; 2011 Jul; 118(2):282-8. PubMed ID: 21527516
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis.
Metheny L; de Lima M
Expert Rev Hematol; 2019 Jan; 12(1):47-60. PubMed ID: 30582393
[TBL] [Abstract][Full Text] [Related]
27. Advances in haploidentical stem cell transplantation for hematologic malignancies.
Montoro J; Sanz J; Sanz GF; Sanz MA
Leuk Lymphoma; 2016 Aug; 57(8):1766-75. PubMed ID: 27424663
[TBL] [Abstract][Full Text] [Related]
28. [Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (part 2)].
Nguyen S; Blaise D; Bay JO; Chevallier P; Contentin N; Dhédin N; Duléry R; Eliaou JF; Rubio MT; Suarez F; Bulabois CE; Cornillon J; Huynh A; Magro L; Michallet M; Paillard C; Turlure P; Yakoub-Agha I;
Pathol Biol (Paris); 2014 Aug; 62(4):185-9. PubMed ID: 24954121
[TBL] [Abstract][Full Text] [Related]
29. Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.
Baumeister SHC; Rambaldi B; Shapiro RM; Romee R
Front Immunol; 2020; 11():191. PubMed ID: 32117310
[TBL] [Abstract][Full Text] [Related]
30. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients.
Kaynar L; Demir K; Turak EE; Öztürk ÇP; Zararsız G; Gönen ZB; Gökahmetoğlu S; Şıvgın S; Eser B; Köker Y; Solmaz M; Ünal A; Çetin M
Hematology; 2017 Apr; 22(3):136-144. PubMed ID: 27724812
[TBL] [Abstract][Full Text] [Related]
31. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
[TBL] [Abstract][Full Text] [Related]
32. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
34. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.
Piemontese S; Ciceri F; Labopin M; Arcese W; Kyrcz-Krzemien S; Santarone S; Huang H; Beelen D; Gorin NC; Craddock C; Gulbas Z; Bacigalupo A; Mohty M; Nagler A;
J Hematol Oncol; 2017 Jan; 10(1):24. PubMed ID: 28103944
[TBL] [Abstract][Full Text] [Related]
35. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
36. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Martínez C; Gayoso J; Canals C; Finel H; Peggs K; Dominietto A; Castagna L; Afanasyev B; Robinson S; Blaise D; Corradini P; Itälä-Remes M; Bermúdez A; Forcade E; Russo D; Potter M; McQuaker G; Yakoub-Agha I; Scheid C; Bloor A; Montoto S; Dreger P; Sureda A;
J Clin Oncol; 2017 Oct; 35(30):3425-3432. PubMed ID: 28846465
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy.
Gao L; Li Y; Zhang Y; Chen X; Gao L; Zhang C; Liu Y; Kong P; Wang Q; Su Y; Wang C; Wang S; Li B; Sun A; Du X; Zeng D; Li J; Liu H; Zhang X
Bone Marrow Transplant; 2014 Apr; 49(4):519-24. PubMed ID: 24464145
[TBL] [Abstract][Full Text] [Related]
38. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
[TBL] [Abstract][Full Text] [Related]
39. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia.
Bonfim C; Ribeiro L; Nichele S; Loth G; Bitencourt M; Koliski A; Kuwahara C; Fabro AL; Pereira NF; Pilonetto D; Thakar M; Kiem HP; Page K; Fuchs EJ; Eapen M; Pasquini R
Biol Blood Marrow Transplant; 2017 Feb; 23(2):310-317. PubMed ID: 27832981
[TBL] [Abstract][Full Text] [Related]
40. [Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Yafour N; Couturier MA; Azarnoush S; Girault S; Hermet E; Masouridi Levrat S; Schmidt A; Michallet M; Etancelin P; Guillaume T; Malard F; Sirvent A; Yakoub-Agha I; Poiré X
Bull Cancer; 2019 Jan; 106(1S):S40-S51. PubMed ID: 30409466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
